9 Ha’Ta’asiya Street
About UroGenUroGen Pharma (“UroGen” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC. In addition, UroGen is developing an additional clinical-stage drug candidate, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer. The company has recently licensed BotuGel for the treatment of overactive bladder and interstitial cystitis, to Allergan for further development.
CEO: Ron Bentsur
CFO: Gary Titus
Please click here for clinical trial information.
36 articles with UroGen
Focused Agreement is on Therapeutic Area of Mutual Interest
UroGen Pharma Ltd., announced that management will present at two investor conferences in March
Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020
UroGen Pharma Ltd. today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering.
UroGen Pharma, based in New York, announced positive topline results from its Phase III OLYMPUS clinical trial. The trial evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC).
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Ms. Barrett Most Recently Served as CEO for Novartis Oncology and Brings a Track Record of Success in Commercial Oncology
Novartis and Pfizer veteran Elizabeth Barrett will take over as the new president and chief executive officer of UroGen Pharma Ltd. Barrett, who most recently helmed Novartis Oncology, will take over as Ron Bentsur steps down from his role as CEO.
UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
UGN-101 Has the Potential to Become the First Drug Ever Approved for LG UTUC
UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment
Following a Recent Pre-New Drug Application Meeting with the FDA for UGN-101, the Company Has Concluded Patient Enrollment in the OLYMPUS Phase 3 Trial for Low-Grade Upper Tract Urothelial Cancer
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
UroGen Pharma Ltd. today announced that management will present at two investor conferences in November 2018
Conference Call and Webcast Scheduled for 8:30 AM ET
UroGen Pharma Ltd. with a focus on uro-oncology, announced that Ron Bentsur, Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 2:30PM Eastern Time.
9/17/2018Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week.
Mr. Mullennix will join the senior management team and will report to Ron Bentsur, UroGen’s CEO.
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. acted as lead manager for the offering.
The offering is expected to close on January 23, 2018, subject to customary closing conditions.
All ordinary shares to be sold in the offering will be offered by the company.
Ms. Cassiano is a communications executive with wide experience in investor relations, corporate communications, media relations, brand strategy and public affairs.